DermBiont

MA - BostonBiotechnology1 H-1B visas (FY2023)

Focus: DermBiont is a Boston-based biotechnology company focused on topical bacterial products for dermatological and infectious disease indications. The company operates as a clinical-stage biotech with a diversified pipeline across immunology, oncology, and infectious diseases.

Immunology Oncology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About DermBiont

AI assessmentNot Hiring

No open roles listed right now. Follow DermBiont to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Swab

Covid19

N/A

Clinical Trials (1)

NCT04668911Oral Health, Microbial Burden and COVID-19

N/A

Help build intelligence for DermBiont

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity with 14 Phase 2 programs across multiple therapeutic areas, offering broad exposure to drug development
Topical bacterial product focus represents a differentiated approach in dermatology with potential for significant unmet medical needs
Boston headquarters provides access to robust pharma/biotech talent pool and ecosystem partnerships

Watch Out For

No current active job openings signals limited near-term hiring or potential organizational contraction
Pre-revenue status with undisclosed funding creates uncertainty around financial runway and job security
No Phase 3 programs in pipeline indicates earliest realistic commercial milestone is 2-3+ years away

Generated by Claude from DermBiont's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Cohort 1 J. Lividum

Interdigital Tinea Pedis

PHASE_2

Clinical Trials (1)

NCT04315051A Trial of Safety/Efficacy of Test Article in Patients With Interdigital T. Pedis

Phase 2

Janthinobacterium lividum

Tinea Pedis

PHASE_2

Clinical Trials (1)

NCT04152226A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis

Phase 2

DBI-102

Hyperpigmentation

PHASE_2

Clinical Trials (1)

NCT05511948Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos

Phase 2

SM-020 gel 1.0%

Seborrheic Keratosis

PHASE_2

Clinical Trials (1)

NCT06108024A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Phase 2

SM-020 gel 1.0%

Dermatosis Papulosa Nigra

PHASE_2

Clinical Trials (1)

NCT06099080A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Phase 2

SM-020

Seborrheic Keratosis

PHASE_2

Clinical Trials (1)

NCT05136144Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis

Phase 2

SM-030 gel 0.64%

Melasma

PHASE_2

Clinical Trials (1)

NCT06454747Randomized Study Using SM-030 Gel for Adults With Melasma

Phase 2

DBI-001 Gel

Tinea Pedis

PHASE_2

Clinical Trials (1)

NCT05493488A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Phase 2

J. lividum

Atopic Dermatitis

PHASE_2

Clinical Trials (1)

NCT04192513Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo

Phase 2

SM-020 1% Gel

Non-Melanoma Skin Cancers

PHASE_2

Clinical Trials (1)

NCT06409195A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

Phase 2

DBI-001

Onychomycosis

PHASE_2

Clinical Trials (1)

NCT05491603A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Phase 2

DBI-002 probiotic gel

Tinea Versicolor

PHASE_2

Clinical Trials (1)

NCT04937920A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor

Phase 2

DBI-001

Atopic Dermatitis

PHASE_2

Clinical Trials (1)

NCT05253755Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 14 clinical trials

Top TAs: Immunology, Infectious Diseases, Oncology

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Immunology

2 pipeline

Infectious Diseases

1 pipeline

Oncology

1 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub